Compugen (NASDAQ:CGEN - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Wednesday, August 6th. Analysts expect Compugen to post earnings of ($0.07) per share and revenue of $3.95 million for the quarter.
Compugen (NASDAQ:CGEN - Get Free Report) last released its quarterly earnings results on Monday, May 19th. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.02). Compugen had a negative return on equity of 24.51% and a negative net margin of 51.27%. The firm had revenue of $2.28 million for the quarter, compared to analyst estimates of $3.70 million. During the same quarter last year, the company earned ($0.08) earnings per share. On average, analysts expect Compugen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Compugen Price Performance
Shares of NASDAQ:CGEN traded down $0.04 on Wednesday, reaching $1.44. The company's stock had a trading volume of 184,629 shares, compared to its average volume of 229,983. Compugen has a 52-week low of $1.13 and a 52-week high of $2.66. The stock's 50-day moving average is $1.62 and its two-hundred day moving average is $1.70. The stock has a market capitalization of $128.51 million, a P/E ratio of -9.00 and a beta of 2.57.
Compugen Company Profile
(
Get Free Report)
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.
See Also
Before you consider Compugen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compugen wasn't on the list.
While Compugen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
